AbCellera Biologics (NASDAQ:ABCL – Get Free Report) was downgraded by research analysts at Benchmark from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, Marketbeat.com reports. A number of other equities research analysts also recently commented on ABCL. The Goldman Sachs Group lowered their price objective on AbCellera […]
AbCellera Biologics (NASDAQ:ABCL – Get Free Report) and Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Earnings and Valuation This table compares AbCellera […]
Operator: Good afternoon, and welcome to AbCellera s Third Quarter 2023 Business Update Conference Call. My name is Kate, and I will facilitate the audio portion of today s interactive broadcast.
Piper Sandler restated their overweight rating on shares of AbCellera Biologics (NASDAQ:ABCL – Free Report) in a report published on Friday morning, Benzinga reports. They currently have a $20.00 price target on the stock. A number of other equities research analysts also recently commented on the company. The Goldman Sachs Group lowered their price objective […]
AbCellera Biologics (NASDAQ:ABCL – Get Free Report)‘s stock had its “overweight” rating reissued by equities researchers at Piper Jaffray Companies in a report issued on Friday, Stock Target Advisor reports. They currently have a $20.00 price objective on the stock. Piper Jaffray Companies’ price target would suggest a potential upside of 402.51% from the company’s […]